Cumulative safety data from three trials testing the reversible direct factor XIa inhibitor asundexian in patients at risk for stroke or recurrent cardiovascular events suggest a better bleeding profile compared with apixaban (Eliquis; Bristol Myers Squibb) in a variety of patient types.